Burden of Herpes Zoster Among Patients with Psoriatic Arthritis in the United States

References

• Lee YW, Park EJ, Kwon IH, Kim KH, Kim KJ. Impact of psoriasis on quality of life: relationship between clinical response to therapy and change in health-related quality of life. Ann Dermatol. 2010;22(4):389–396. doi:10.5021/ad.2010.22.4.389
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940–946. doi:10.1001/jamadermatol.2021.2007
   PubMed Web of Science ®Google Scholar
• Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265.e219. doi:10.1016/j.jaad.2018.06.027
   PubMed Web of Science ®Google Scholar
• Busse K, Liao W. Which psoriasis patients develop psoriatic arthritis? Psoriasis Forum. 2010;16(4):17–25. doi:10.1177/247553031016a00403
   PubMedGoogle Scholar
• Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5–32. doi:10.1002/art.40726
   PubMed Web of Science ®Google Scholar
• Siegel SAR, Winthrop KL. In the real world: infections associated with biologic and small molecule therapies in psoriatic arthritis and psoriasis. Curr Rheumatol Rep. 2019;21(7):36. doi:10.1007/s11926-019-0832-y
   PubMed Web of Science ®Google Scholar
• Galloway J, Raine T, Rivett L, Roberts J, Dews SA, Choy EH. Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination. Clin Exp Rheumatol. 2022;40(7):1432–1441. doi:10.55563/clinexprheumatol/0jdyse
   PubMed Web of Science ®Google Scholar
• Yun H, Yang S, Chen L, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68(9):2328–2337. doi:10.1002/art.39670
   PubMed Web of Science ®Google Scholar
• Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84(3):274–280. doi:10.4065/84.3.274
   PubMed Web of Science ®Google Scholar
• Kalogeropoulos CD, Bassukas ID, Moschos MM, Tabbara KF. Eye and periocular skin involvement in herpes zoster infection. Med Hypothesis Discov Innov Ophthalmol. 2015;4(4):142–156.
   PubMedGoogle Scholar
• Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37. doi:10.1186/1741-7015-8-37
   PubMed Web of Science ®Google Scholar
• Matthews S, De Maria A, Passamonti M, et al. The economic burden and impact on quality of life of herpes zoster and postherpetic neuralgia in individuals aged 50 years or older in Italy. Open Forum Infect Dis. 2019;6(2):ofz007. doi:10.1093/ofid/ofz007
   PubMed Web of Science ®Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory committee on immunization practices (ACIP) centers for disease control and prevention (CDC). prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2008;57(RR–5):1–30; quiz CE32–34.
   Google Scholar
• Curran D, Callegaro A, Fahrbach K, et al. Meta-regression of herpes zoster incidence worldwide. Infect Dis Ther. 2022;11(1):389–403. doi:10.1007/s40121-021-00567-8
   PubMed Web of Science ®Google Scholar
• Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2019;81(1):102–110. doi:10.1016/j.jaad.2019.03.017
   PubMed Web of Science ®Google Scholar
• Hagberg KW, Persson R, Vasilakis-Scaramozza C, et al. Herpes zoster, hepatitis C, and tuberculosis risk with apremilast compared to biologics, DMARDs and corticosteroids to treat psoriasis and psoriatic arthritis. Clin Epidemiol. 2020;12:153–161. doi:10.2147/CLEP.S239511
   PubMed Web of Science ®Google Scholar
• Jafari AJ, Owens KS, Yang S, et al. Differences in risk of herpes zoster infection across medication classes among psoriasis patients: a case-control study. Int J Dermatol. 2023;62(6):e333–e335. doi:10.1111/ijd.16305
   PubMed Web of Science ®Google Scholar
• Chiu HY, Hung YT, Huang SW, Huang YH. Comparative risk of herpes zoster in patients with psoriatic disease on systemic treatments: a systematic review and network meta-analysis. Ther Adv Chronic Dis. 2022;13:20406223221091188. doi:10.1177/20406223221091188
   Web of Science ®Google Scholar
• Zisman D, Bitterman H, Shalom G, et al. Psoriatic arthritis treatment and the risk of herpes zoster. Ann Rheum Dis. 2016;75(1):131–135. doi:10.1136/annrheumdis-2013-205148
   PubMed Web of Science ®Google Scholar
• Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537–1550. doi:10.1056/NEJMoa1615975
   PubMed Web of Science ®Google Scholar
• Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525–1536. doi:10.1056/NEJMoa1615977
   PubMed Web of Science ®Google Scholar
• Zou A, Chen Y, Shi N, Ye Y. Risk of herpes zoster associated with biological therapies for psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Medicine (Baltimore). 2021;100(40):e27368. doi:10.1097/MD.0000000000027368
   PubMed Web of Science ®Google Scholar
• Dooling KL, Guo A, Patel M, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103–108. doi:10.15585/mmwr.mm6703a5
   PubMed Web of Science ®Google Scholar
• Anderson TC, Masters NB, Guo A, et al. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the advisory committee on immunization practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(3):80–84. doi:10.15585/mmwr.mm7103a2
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi:10.1093/aje/kwq433
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of Labor Statistics. Measuring price change in the CPI: medical care. Available from: https://www.bls.gov/cpi/factsheets/medical-care.htm. Accessed Jun 26, 2023.
   Google Scholar
• Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. New York: Lawrence Erlbaum Associates; 1988.
   Google Scholar
• Faraone SV. Interpreting estimates of treatment effects: implications for managed care. P T. 2008;33(12):700–711.
   PubMedGoogle Scholar
• Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42(2):325–334. doi:10.1007/s15010-013-0550-8
   PubMed Web of Science ®Google Scholar
• Takeshita J, Shin DB, Ogdie A, Gelfand JM. Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom. J Invest Dermatol. 2018;138(8):1726–1735. doi:10.1016/j.jid.2018.01.039
   PubMed Web of Science ®Google Scholar
• Min C, Yoo DM, Kim M, Choi HG. Increased risk of herpes zoster in patients with psoriasis: a longitudinal follow-up study using a national sample cohort. Australas J Dermatol. 2021;62(2):183–189. doi:10.1111/ajd.13534
   PubMed Web of Science ®Google Scholar
• Tsai SY, Chen HJ, Lio CF, et al. Increased risk of herpes zoster in patients with psoriasis: a population-based retrospective cohort study. PLoS One. 2017;12(8):e0179447. doi:10.1371/journal.pone.0179447
   PubMed Web of Science ®Google Scholar
• Singer D, Thompson-Leduc P, Ma S, et al. Burden of herpes zoster among patients with psoriasis in the United States. Dermatol Ther (Heidelb). 2023;13(11):2649–2668. doi:10.1007/s13555-023-00988-y
   PubMedGoogle Scholar
• Wu KK, Lee MP, Lee EB, Wu JJ. Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions. J Dermatolog Treat. 2020;31(4):359–365. doi:10.1080/09546634.2019.1597246
   PubMed Web of Science ®Google Scholar
• Al Sawah S, Foster SA, Goldblum OM, et al. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. J Med Econ. 2017;20(9):982–990. doi:10.1080/13696998.2017.1345749
   PubMed Web of Science ®Google Scholar
• Merola JF, Dennis N, Chakravarty SD, et al. Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA–a retrospective study of claims data from 2009 to 2020. Clin Rheumatol. 2021;40(10):4061–4070. doi:10.1007/s10067-021-05713-8
   PubMed Web of Science ®Google Scholar
• Singer D, Thompson-Leduc P, Poston S, et al. Clinical and economic burden of herpes zoster in patients with rheumatoid arthritis: a retrospective cohort study using administrative claims. Rheumatol Ther. 2023;10(4):933–950. doi:10.1007/s40744-023-00549-x
   PubMed Web of Science ®Google Scholar
• Singer D, Thompson-Leduc P, Gupta D, et al. Economic and clinical burden of herpes zoster among patients with inflammatory bowel disease in the United States. Crohns Colitis 360. 2023;5(3):otad033. doi:10.1093/crocol/otad033
   PubMedGoogle Scholar
• Elze MC, Gregson J, Baber U, et al. Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies. J Am Coll Cardiol. 2017;69(3):345–357. doi:10.1016/j.jacc.2016.10.060
   PubMed Web of Science ®Google Scholar
• Yawn BP, Itzler RF, Wollan PC, Pellissier JM, Sy LS, Saddier P. Health care utilization and cost burden of herpes zoster in a community population. Mayo Clin Proc. 2009;84(9):787–794. doi:10.4065/84.9.787
   PubMed Web of Science ®Google Scholar
• Benbernou A, Drolet M, Levin MJ, et al. Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. Eur J Pain. 2011;15(10):1100–1106. doi:10.1016/j.ejpain.2011.04.014
   PubMed Web of Science ®Google Scholar
• Klompas M, Kulldorff M, Vilk Y, Bialek SR, Harpaz R. Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. Mayo Clin Proc. 2011;86(12):1146–1153. doi:10.4065/mcp.2011.0305
   PubMed Web of Science ®Google Scholar